Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick Research. Delhi, July 11, 2025 (GLOBE ...

Only with the adoption of digital imaging and AI-powered analysis will next-generation precision oncology therapies reach their full potential and ensure no eligible patient is overlooked.

Thousands of women battling advanced breast cancer could be denied access to crucial life-extending medication due to an ...

AstraZeneca and Daiichi Sankyo have the confirmatory trial data they were hoping for with Enhertu as a treatment for advanced, HER2-positive breast cancer in previously-treated patients. The ...

The documents show that blockbuster cancer drugs like pembrolizumab (brand Keytruda), osimertinib (brand Tagrisso), and ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

The list recommending customs duty of 5% includes 74 drugs, while another suggesting full exemption has 69 drugs. A separate ...

Leah Hughes was 29 when she first noticed a lump in her breast — but when she told her doctor, they brushed it off as a ...

This year's American Society of Clinical Oncology (ASCO) meeting delivered a packed agenda of breast cancer research, with major updates for antibody-drug conjugates, HER2-positive regimens, and ...

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.